Yes, I understand that by a stroke of luck we happened to have 215 patients dosed in 2014 which will add to our safety record against COVID in 2021.
That wasn't why we ran that trial though. Something went terribly wrong with that indication. If it was really worth $1B/year we would have partnered up to get the $30M. So either no BP was willing to pay or Leo felt that quadrupling the shares since then (selling 75% of the company) was better than taking a deal.